Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS, Hong DS, Girard P, El Bawab S. Xiong W, et al. CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):428-440. doi: 10.1002/psp4.12602. Epub 2021 May 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33818908 Free PMC article.
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. Falchook GS, et al. Among authors: xiong w. Clin Cancer Res. 2020 Mar 15;26(6):1237-1246. doi: 10.1158/1078-0432.CCR-19-2860. Epub 2019 Dec 10. Clin Cancer Res. 2020. PMID: 31822497 Clinical Trial.
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R. Xiong W, et al. Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. doi: 10.1007/s00280-022-04441-3. Epub 2022 Jun 30. Cancer Chemother Pharmacol. 2022. PMID: 35771259 Free PMC article. Clinical Trial.
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Grisic AM, Xiong W, Tanneau L, Jönsson S, Friberg LE, Karlsson MO, Dai H, Zheng J, Girard P, Khandelwal A. Grisic AM, et al. Among authors: xiong w. Clin Cancer Res. 2022 Apr 1;28(7):1363-1371. doi: 10.1158/1078-0432.CCR-21-2662. Clin Cancer Res. 2022. PMID: 34921021 Free PMC article.
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R. Tsimberidou AM, et al. Among authors: xiong w. J Hematol Oncol. 2021 Aug 18;14(1):127. doi: 10.1186/s13045-021-01132-z. J Hematol Oncol. 2021. PMID: 34407844 Free PMC article. Clinical Trial.
Hyperglycemia Inhibits AAA Expansion: Examining the Role of Lysyl Oxidase.
Jespersen KE, Xiong W, Santhanam L, Terrin M, Matsumura J, Curci JA, Blackwelder W, Brown CH, Martinez Yus M, Baxter BT. Jespersen KE, et al. Among authors: xiong w. Am J Physiol Heart Circ Physiol. 2024 Dec 24. doi: 10.1152/ajpheart.00163.2024. Online ahead of print. Am J Physiol Heart Circ Physiol. 2024. PMID: 39716889
4,948 results